Tirzepatide: Pharmacology, Trial Data and Why We Don't Sell It
How tirzepatide's dual GIP/GLP-1 agonism works, what SURMOUNT and SURPASS showed, and why the closest research-grade analog is retatrutide.
TL;DR: What this article covers
What it is: Tirzepatide (Mounjaro, Zepbound) is a 39-amino-acid dual GIP/GLP-1 receptor co-agonist that produced the largest weight loss seen in a phase 3 obesity trial to date.
The evidence: SURMOUNT-1 showed up to -20.9% mean weight loss at 72 weeks (PMID 35658024); SURPASS-2 showed tirzepatide beating semaglutide 1 mg head to head on both HbA1c and weight (PMID 34170647).
The legal reality: Tirzepatide is an EMA-approved, patent-protected prescription medicine. We do not sell it, and no legitimate research-chemical supplier can.
Our angle: We carry retatrutide, the related triple GIP/GLP-1/glucagon agonist, for laboratory research. Its phase 2 data (-24.2% at 48 weeks, PMID 37366315) is the closest published comparator to tirzepatide's mechanism.
Few molecules have reshaped a therapeutic category as fast as tirzepatide did to incretin-based metabolic medicine. Since its first phase 3 obesity results in 2022, it has become the reference point every newer compound, including the ones covered on this site, gets measured against. This article explains what tirzepatide is, how it works, what its trials actually showed, and why, precisely because of how successful and tightly protected it is, we do not sell it and never will.
What is tirzepatide? Origin and structure
Tirzepatide is a synthetic peptide of 39 amino acids, developed by Eli Lilly and marketed under two brand names depending on the approved indication: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is administered once weekly by subcutaneous injection.
Structurally, tirzepatide is built on a peptide backbone that engages two different incretin hormone receptors, attached to a C20 fatty diacid side chain. That fatty-acid modification is what gives the molecule its pharmacokinetic signature: it binds circulating albumin, which slows renal clearance and extends the elimination half-life to roughly five days, the reason a single injection covers a full week.
Tirzepatide is EMA-approved and has been marketed as a prescription-only medicinal product across the EU since 2023. It sits within a family of engineered incretin mimetics that also includes semaglutide (GLP-1 mono-agonist) and, in the research-chemical space, retatrutide (a triple agonist we address later in this article).
Mechanism of action: dual GIP/GLP-1 receptor agonism explained
Tirzepatide's defining feature is that it activates two receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Both are native incretin hormone receptors involved in glucose-dependent insulin secretion, but they had, until tirzepatide, mostly been drugged separately.
The binding profile is deliberately asymmetric. Tirzepatide binds the GIP receptor with an affinity close to that of the native hormone, while behaving as an imbalanced agonist that favours GIP-receptor signalling over its GLP-1-receptor activity. This is not a design flaw: it is an engineered bias intended to balance potent GIP signalling against a GLP-1 effect calibrated to reduce gastrointestinal tolerability issues while preserving efficacy.
Mechanistically, GIP and GLP-1 receptor agonism combine in a way that is more than additive. Reviewing the SURPASS trial program's pharmacology, combined GIP and GLP-1 receptor agonism produces synergistic insulinotropic and glucagonostatic effects, meaning greater glucose-dependent insulin release and greater suppression of glucagon than either incretin pathway achieves alone (PMID 33325008). On top of the glycaemic effects, GLP-1R agonism slows gastric emptying and acts on appetite centres in the hypothalamus and brainstem, which is the principal driver of the weight loss seen in trials.
Why GIP was ever added to a GLP-1 drug
For years, GIP was considered a weaker, secondary incretin, partly because its insulin-releasing effect is blunted in people with type 2 diabetes. Tirzepatide's clinical program was the first to demonstrate at scale that co-agonism, rather than GIP alone, restores and amplifies the pathway's contribution when paired with GLP-1R activation. This finding is a large part of why every next-generation incretin candidate since, including triple agonists, layers GIP activity onto a GLP-1 backbone rather than dropping it.
The clinical evidence: SURMOUNT and SURPASS trial programs
Tirzepatide's regulatory approvals rest on two large phase 3 programs: SURPASS (type 2 diabetes) and SURMOUNT (obesity/weight management).
SURMOUNT-1 (PMID 35658024) was the pivotal 72-week obesity trial, enrolling 2,539 adults without diabetes. Across the three studied doses, mean weight loss was:
- 5 mg: -15.0%
- 10 mg: -19.5%
- 15 mg: -20.9%
- Placebo: -3.1%
At the highest dose, up to 57% of participants lost 20% or more of their body weight, a magnitude of effect that had not previously been documented for a pharmacological (non-surgical) obesity treatment in a phase 3 trial.
SURPASS-2 (PMID 34170647) tested tirzepatide head to head against semaglutide 1 mg, at the time the leading GLP-1-only agent, in 1,879 people with type 2 diabetes. Tirzepatide's three doses reduced HbA1c by -2.01, -2.24 and -2.30 percentage points respectively, versus -1.86 points for semaglutide. Weight loss was 1.9 to 5.5 kg greater with tirzepatide depending on dose. This was the first large head-to-head trial to establish clinical superiority of a dual agonist over a best-in-class GLP-1 mono-agonist on both glycaemic and weight endpoints simultaneously.
Together, the two programs are what underpin tirzepatide's EMA approval and its rapid adoption as, by most measures, the most effective pharmacological obesity and diabetes treatment on the market at the time of its launch.
What the community reports
Beyond the trial data, tirzepatide is heavily discussed in online health and fitness communities. Important caveat: Reddit could not be verified as a source for this article; nothing here is attributed to r/Peptides, r/PeptideCycles or r/tirzepatide. The material below is drawn from MESO-Rx (thinksteroids.com/community), a long-running peptide and anabolic-steroid discussion forum, with usernames omitted. Treat all of it as anecdotal, not clinical evidence.
Recurring themes on the forum: posters generally follow the official titration schedule (2.5, 5, 7.5, 10, 12.5, 15 mg, stepped up roughly every four weeks) but frequently experiment with splitting the weekly dose into smaller Monday/Wednesday/Friday or every-other-day injections, aiming to avoid a "trough" hunger rebound felt in the last day or two before the next shot. Appetite suppression is often described as starting the same day as a first, low dose, alongside early water-weight loss.
Tolerance complaints are common: several posters report appetite suppression fading by day five or six after months at a stable dose, prompting debate over raising the dose, shortening the interval, or adding another compound (cagrilintide came up in that context). Side-effect chatter centres on gastrointestinal issues (nausea, especially after fatty meals, stomach pain, bloating when dosed more than weekly) and fatigue lasting two to three days post-injection, with occasional reports of insomnia or injection-site sensitivity.
Some threads cross over with bodybuilding and cutting culture, with posters comparing tirzepatide favourably to older fat-loss compounds like clenbuterol, though others push back that it is a supplement to diet and training discipline, not a replacement for it. A distinct and recurring topic is sourcing anxiety: one thread involved users cross-checking whether same-colour vial caps from a vendor actually indicated a single reliable source, with a poster cautioning that cap colour alone says nothing about quality. Another described a vendor losing community trust after allegedly disputing a failed third-party Janoshik lab result and being dropped from a peer testing group's approved list, reinforcing a forum norm of demanding independently verified CoAs over vendor claims.
Separately, secondary web sources note that the legal footing of compounded tirzepatide has tightened since the FDA removed it from the drug-shortage list in late 2024, ending 503A compounding in 2025, with further restriction of 503B outsourcing floated in 2026; at least one large "research peptide" vendor reportedly wound down in March 2026. Overall community sentiment reads as positive but pragmatic: enthusiasm paired with troubleshooting rather than pure hype. One fringe claim worth flagging: suggestions in secondary content that tirzepatide has meaningful "longevity" benefits beyond its metabolic effects are speculative and not supported by any trial data reviewed for this article.
Why we do not sell tirzepatide
Tirzepatide is a patented, EMA-approved prescription drug, not a research chemical
Tirzepatide is protected by active Eli Lilly composition-of-matter and use patents extending into the 2030s, and it is classified across the EU as a licensed, prescription-only medicinal product (Mounjaro, Zepbound). Under EU medicines law, it can only be dispensed through licensed pharmacy channels against a valid prescription. We do not sell tirzepatide, Mounjaro or Zepbound in any form, and we make no claim, implied or otherwise, that any product on this site provides access to it or replicates its effects. Any vendor advertising "tirzepatide peptide" for research purposes is doing so in a legal grey or black zone given the drug's active patent and prescription status, and we would advise treating such offers with serious caution.
This is not a matter of our commercial preference. A patented, approved medicine sold outside licensed pharmacy channels is a legal and safety problem, full stop. Our catalogue is limited to peptides that are not patented approved drugs and that are supplied and marketed strictly for laboratory research use.
The research-peptide alternative we carry: retatrutide
If the mechanism that makes tirzepatide interesting, incretin receptor co-agonism, is what a researcher wants to study, the closest molecule we carry is retatrutide, sometimes referred to by its development code LY3437943. Where tirzepatide is a dual GIP/GLP-1 agonist, retatrutide extends the same design logic one step further: it is a triple agonist, activating GLP-1, GIP, and the glucagon receptor simultaneously.
The added glucagon receptor activity is mechanistically distinct from anything in tirzepatide's profile. Glucagon receptor agonism increases hepatic energy expenditure and promotes fatty acid oxidation, an axis that GIP/GLP-1 co-agonism alone does not touch. In principle, this gives retatrutide an additional lever on energy balance beyond appetite suppression and delayed gastric emptying, which is the theoretical basis for why its measured effect size in trials has been larger than tirzepatide's.
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
How retatrutide's trial data compares to tirzepatide's
In its own phase 2 trial, retatrutide produced a mean weight loss of -24.2% at the 12 mg dose after 48 weeks, versus -2.1% for placebo (PMID 37366315). Set against SURMOUNT-1's -20.9% at tirzepatide's top 15 mg dose over the longer 72-week window, retatrutide's phase 2 result is the larger effect size recorded to date for a GLP-1-pathway incretin agonist, in a cross-trial comparison.
Two caveats matter for anyone reading these numbers side by side. First, retatrutide's data comes from a phase 2 trial (smaller sample, shorter regulatory scrutiny) versus tirzepatide's phase 3 program, so the comparison is illustrative of mechanism, not a formal statistical head-to-head. Second, retatrutide is not an approved medicine and is not a substitute, equivalent, or research-grade proxy for obtaining tirzepatide's clinical effects in humans. It is supplied here exclusively for laboratory research into triple-agonist incretin pharmacology, consistent with the legal and safety framing on every product page in our catalogue.
A note on cross-trial comparison methodology
Comparing percentage weight loss figures across separate phase 2 and phase 3 trials, run at different times with different populations and protocols, is directionally informative but not the same as a randomised head-to-head. Differences in trial duration (48 vs. 72 weeks), sample size, and baseline characteristics can all move the topline number. Researchers should treat cross-trial figures as hypothesis-generating, not as proof of comparative superiority.
Questions about availability
Any questions about tirzepatide's legal status, availability, or where it can legitimately be obtained on prescription should be directed to a licensed pharmacy or your treating physician. For questions about our retatrutide research peptide or any other product in our catalogue, our team can be reached at [email protected].
FAQ
This article is for informational and educational purposes only. All mentioned peptides are intended exclusively for laboratory research and not for human consumption. We do not sell the drug this article is about. For Research Purposes Only.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.